rs769139957
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_020778.5(ALPK3):c.1417delC(p.Gln473SerfsTer30) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000622 in 1,606,618 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_020778.5 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000659 AC: 1AN: 151786Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000205 AC: 5AN: 243794Hom.: 0 AF XY: 0.00000760 AC XY: 1AN XY: 131606
GnomAD4 exome AF: 0.00000619 AC: 9AN: 1454832Hom.: 0 Cov.: 33 AF XY: 0.00000691 AC XY: 5AN XY: 723264
GnomAD4 genome AF: 0.00000659 AC: 1AN: 151786Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74114
ClinVar
Submissions by phenotype
Cardiomyopathy Pathogenic:1
- -
not provided Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gln675Serfs*30) in the ALPK3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ALPK3 are known to be pathogenic (PMID: 21441111, 26846950, 27106955, 34263907). This variant is present in population databases (rs769139957, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with ALPK3-related conditions (PMID: 28630369, 33191771). ClinVar contains an entry for this variant (Variation ID: 427757). For these reasons, this variant has been classified as Pathogenic. -
Cardiovascular phenotype Pathogenic:1
The c.2023delC pathogenic mutation, located in coding exon 5 of the ALPK3 gene, results from a deletion of one nucleotide at nucleotide position 2023, causing a translational frameshift with a predicted alternate stop codon (p.Q675Sfs*30). This alteration has been reported as homozygous in two individuals with cardiomyopathy and as compound heterozygous with a missense alteration in ALPK3 in another individual with cardiomyopathy (Çalayan AO et al. Cold Spring Harb Mol Case Stud, 2017 Sep;3:[ePub ahead of print]; Herkert JC et al. Am Heart J, 2020 07;225:108-119). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
ALPK3-related disorder Pathogenic:1
The ALPK3 c.2023delC variant is predicted to result in a frameshift and premature protein termination (p.Gln675Serfs*30). This variant has been reported in the homozygous and compound heterozygous states in individuals with early-onset cardiomyopathy (Table II and Table SI, Herkert et al. 2020. PubMed ID: 32480058; Çağlayan et al. 2017. PubMed ID: 28630369). In the heterozygous state, this variant was documented in multiple individuals from one family with adult-onset hypertrophic cardiomyopathy in one study (Cheawsamoot et al. 2020. PubMed ID: 33191771), while this variant was also found in apparently unaffected carriers in another study (Çağlayan et al. 2017. PubMed ID: 28630369), suggesting an increased risk with reduced penetrance in the heterozygous state. This variant is reported in 0.0055% of alleles in individuals of East Asian descent in gnomAD. Frameshift variants in ALPK3 are expected to be pathogenic. This variant is interpreted as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at